ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Impending Generic Competition Forces Innovation In Alzheimer's Treatments
As the Baby Boomer
generation reaches retirement age, the number of Americans suffering
from Alzheimer's disease is expected to jump from 5 million to about
14 million in 2050. Meanwhile, several patents for Alzheimer's
treatments are approaching expiration, and developers are working on
innovations in anticipation of impending generic competition,
according to a newly published report from Kalorama Information,
"World Alzheimer's Disease Market (Incidence, Treatments, Key
Companies, Pipeline and Trends)."
Demand for Alzheimer's treatments has surged over the past decade --
sales grew a healthy 17.3% annually from 2005 to 2007. Though growth
is expected to continue at a strong 6.7% annual rate through 2012,
this is significantly slower than before, and can be attributed to a
sudden drop in growth after 2010 as a number of drugs near patent
expirations and generic companies prepare to launch equivalent
products. Teva, Dr. Reddy's, Ranbaxy, Mylan, Barr, Sun Pharma,
Genpharm, Lupin, and Wockhardt are all expected to have generic
versions of some of the world's largest Alzheimer's drugs on the
market by 2010.
"Eisai's Aricept, which has the lion's share of the market, is a
prime target for generic competition," notes Mellisa Elder, Kalorama
Information's pharmaceutical analyst. "Its patent is still
enforceable as it was granted in 1990. But Eisai has been fighting
with Teva, Mutual and United Research Labs, and more court
proceedings are expected."
To counter the imminent generic onslaught, several developers are
offering promising innovative treatments in all phases of development,
including Eisai's sustained release formulation of Aricept SR which is
in phase III development. The number of new drugs in development has
increased, from about 20 in 2005 to almost 60 in 2007.
Kalorama Information's report "World Alzheimer's Disease Market
(Incidence, Treatments, Key Companies, Pipeline and Trends)" provides
a worldwide overview of this multi-billion dollar market. A market
analysis by product and region, products in development and forecasts
through 2012 are included, along with a competitive analysis and key
company profiles. For further information hclick here.
About Kalorama Information
Kalorama Information supplies the latest in independent market
research in the life sciences, as well as a full range of custom
research services. Kalorama routinely assists the media with
healthcare topics, and can provide experts to speak about markets in
the life sciences industry.
Kalorama Information
View drug information on ARICEPT.
Iminente Generic Concurenþã Forþelor inovare în Alzheimer Tratamente - Impending Generic Competition Forces Innovation In Alzheimer's Treatments - articole medicale engleza - startsanatate